Asset Details
Do you wish to reserve the book?
Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report
Do you wish to request the book?
Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report
2018
Overview
Background
Propionic acidemia is a rare autosomal recessive inherited metabolic disorder that can inhibit the synthesis of
N
-acetylglutamate, the obligatory activator in urea synthesis, leading to hyperammonemia.
N
-carbamylglutamate ameliorates hyperammonemia in decompensated propionic acidemia. The effects of long-term continuous
N
-acetylglutamate administration in such patients are unknown. We report our clinical experience with continuous administration of
N
-acetylglutamate for 6 years in a patient with propionic acidemia frequently presenting with hyperammonemia.
Case presentation
A male Caucasian patient with frequently decompensated propionic acidemia and hyperammonemia was admitted 78 times for acute attacks during the first 9 years of his life. Continuous daily treatment with oral
N
-carbamylglutamate 100 mg/kg (50 mg/kg after 6 months) was initiated. During 6 years of treatment, he had a significant decrease in his mean plasma ammonia levels (75.7 μmol/L vs. 140.3 μmol/L before
N
-carbamylglutamate therapy,
p
< 0.005 [normal range 50–80 μmol/L]) and fewer acute episodes (two in 6 years).
Conclusion
Our results suggest a benefit of
N
-acetylglutamate administration outside the emergency setting. If this observation is confirmed, future studies should aim to optimize the dosage and explore effects of the dosage requirements on other drugs and on protein tolerance.
Publisher
BioMed Central,BioMed Central Ltd,BMC
